News

A drug targeting the cause of Huntington’s disease (HD) was found effective and safe in animal tests, and clinical studies in humans are beginning, according to newly released data that will be presented at the American Academy of Neurology‘s 68th Annual Meeting in Vancouver, Canada, on April 15–21, 2016. The…

Researchers from the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland, led by Dr. Matteo Cornaglia, PhD, have developed a new experimental device that can assist scientists in the analysis of molecular pathway studies related to complex human dysfunctions, such as neurodegenerative diseases like Huntington’s (HD). The device is intended for use with the…

Researchers have developed a computational cognitive classification method that allows the differentiation of pre-symptomatic Huntington’s disease patients from early onset patients and healthy subjects, an approach that demonstrates promise for classification and prediction of brain disorders. The research paper, “A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease,” was published…

The National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) awarded researchers at The Scripps Research Institute (TSRI) in Jupiter, Florida a $1.7 million grant to analyze which mechanisms contribute to Huntington’s disease. Huntington’s disease is an inherited disorder which results from a malformation in…

UCB and Baylor College of Medicine have announced a strategic research alliance to discover therapies for people with neurodegenerative conditions, such as Huntington’s disease (HD). The research effort will be conducted by Dr. Huda Zoghbi, professor of molecular and human genetics, pediatrics, neurology and neuroscience at Baylor College of…

Researchers have for the first time visualized the structure of the protein α-synuclein in healthy living cells, allowing a better understanding of why the protein forms aggregates in Huntington’s disease (HD) and other neurodegenerative diseases. Despite α-synuclein being a known component of amyloid aggregates forming in the brains of HD, Parkinson’s and…

Two scientists at Cambridge University used differing techniques to better understand how brain cells form connections, research that may inspire new ways of rewiring the brain to repair nerves and treat diseases such as Huntington’s. Professor Christine Holt of the Department of Physiology, Development and Neuroscience, focused on how molecules influence neurons…

Researchers found that the mutant huntingtin protein aggregates characteristic of Huntington’s disease have distinctive structural features, a discovery that might help to uncover the disease’s underlying mechanisms and lead to new therapies. The study, “Huntingtin exon 1 fibrils feature an interdigitated β-hairpin–based polyglutamine core,” was published in Proceedings of the National…

A research team successfully developed a virus variant that is more efficient than the current standard at crossing the blood-brain barrier and delivering genes to the central nervous system (CNS), making it a promising gene therapy approach to treating neurodegenerative diseases such as Huntington’s disease. The blood-brain barrier, made up of specialized…

A review published in the journal Nature and Science of Sleep explores the links between sleep disturbance and neurodegeneration in diseases such as Huntington’s disease (HD). The authors state that sleep difficulties might not only be a symptom of the underlying neurodegeneration but also a contributing factor driving…